小鼠肥大细胞瘤P815在几乎完全被排斥后逃逸是由于抗原缺失变体，而非免疫抑制。
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
作者信息
Uyttenhove C, Maryanski J, Boon T
出版信息
J Exp Med. 1983 Mar 1;157(3):1040-52. doi: 10.1084/jem.157.3.1040.
Abstract
Even though mastocytoma P815 often undergoes a nearly complete rejection in syngeneic mice, the tumor cells almost always escape to form progressive tumors. We found that this was not due to the establishment of an immunosuppressed state because genetically marked P815 cells, that were injected in mice where tumor escape was occurring, were readily rejected. An analysis of escaping tumor cell populations with anti-P815 cytolytic T lymphocyte (CTL) clones showed the presence of stable resistant variants. Using antigen-loss variants found in escaping populations or selected in vitro with CTL clones, we were able to define four different tumor-associated antigenic specificities, each recognized by a specific CTL clone. One of these specificities was absent from all escaping tumor cells and another had been lost by some of them.
摘要
尽管肥大细胞瘤P815在同基因小鼠中常常几乎完全被排斥，但肿瘤细胞几乎总是逃脱并形成进行性肿瘤。我们发现这并非由于建立了免疫抑制状态，因为在肿瘤正在发生逃脱的小鼠中注射的基因标记的P815细胞很容易被排斥。用抗P815细胞溶解T淋巴细胞（CTL）克隆对逃脱的肿瘤细胞群体进行分析，结果显示存在稳定的抗性变体。利用在逃脱群体中发现的或用CTL克隆在体外选择的抗原缺失变体，我们能够确定四种不同的肿瘤相关抗原特异性，每种特异性都由一个特定的CTL克隆识别。所有逃脱的肿瘤细胞中都不存在其中一种特异性，而其中一些细胞已经失去了另一种特异性。
相似文献
1
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.小鼠肥大细胞瘤P815在几乎完全被排斥后逃逸是由于抗原缺失变体，而非免疫抑制。
J Exp Med. 1983 Mar 1;157(3):1040-52. doi: 10.1084/jem.157.3.1040.
2
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。IV. 用细胞溶解T细胞克隆选择抗原缺失变体分析变体特异性抗原。
Eur J Immunol. 1982 May;12(5):406-12. doi: 10.1002/eji.1830120509.
3
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。VI. 由于抗原缺失继发变体导致偶尔逃避宿主排斥反应。
Int J Cancer. 1983 Jan 15;31(1):119-23. doi: 10.1002/ijc.2910310119.
4
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。III. 同基因细胞溶解型T淋巴细胞反应的克隆分析。
Eur J Immunol. 1982 May;12(5):401-6. doi: 10.1002/eji.1830120508.
5
Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.同种异体抗原诱导的针对同基因肿瘤细胞的细胞毒性：克隆水平分析。
J Immunol. 1984 Jun;132(6):3218-25.
6
Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.体内针对p815小鼠肿瘤的细胞毒性T淋巴细胞反应中的复发性T细胞受体重排。
J Exp Med. 1996 Feb 1;183(2):439-49. doi: 10.1084/jem.183.2.439.
7
Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.表达不相容次要组织相容性抗原的肿瘤在生长方面的差异抗性反映的是调节性影响，而非抗次要组织相容性细胞毒性T淋巴细胞前体频率的差异。
Cell Immunol. 1985 Mar;91(1):100-10. doi: 10.1016/0008-8749(85)90035-8.
8
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。I. 同基因小鼠的排斥反应。
J Exp Med. 1980 Nov 1;152(5):1175-83. doi: 10.1084/jem.152.5.1175.
9
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。VII. 变体抗原在体细胞杂种中的显性表达。
Somatic Cell Genet. 1983 May;9(3):345-57. doi: 10.1007/BF01539143.
10
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。II. T淋巴细胞介导的细胞溶解作用。
J Exp Med. 1980 Nov 1;152(5):1184-93. doi: 10.1084/jem.152.5.1184.
引用本文的文献
1
Antigenic cancer persister cells survive direct T cell attack.抗原性癌症持久性细胞能在T细胞的直接攻击下存活。
bioRxiv. 2025 Mar 17:2025.03.14.643359. doi: 10.1101/2025.03.14.643359.
2
Expansion of tumor-reactive CD8 T cell clonotypes occurs in the spleen in response to immune checkpoint blockade.肿瘤反应性 CD8 T 细胞克隆型的扩增发生在脾脏中，以响应免疫检查点阻断。
Sci Immunol. 2024 Sep 13;9(99):eadi3487. doi: 10.1126/sciimmunol.adi3487.
3
Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy.癌症免疫疗法中基于脂质体的原位抗原修饰策略用于“通用”T细胞受体工程化T细胞
MedComm (2020). 2024 Jul 7;5(7):e618. doi: 10.1002/mco2.618. eCollection 2024 Jul.
4
Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.肿瘤内注射 BCG Ag85A 高亲和力肽增强了 PPD 阳性黑色素瘤的抗肿瘤疗效。
Cancer Immunol Immunother. 2024 Apr 17;73(6):103. doi: 10.1007/s00262-024-03693-7.
5
Bacterial Drug Delivery Systems for Cancer Therapy: "Why" and "How".用于癌症治疗的细菌药物递送系统：“为何”与“如何”
Pharmaceutics. 2023 Aug 27;15(9):2214. doi: 10.3390/pharmaceutics15092214.
6
Targeting cancer testis antigens in synovial sarcoma.针对滑膜肉瘤中的癌症睾丸抗原。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002072.
7
The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.质谱技术和蛋白质基因组学在 HLA 表位预测中的作用。
Proteomics. 2018 Jun;18(12):e1700259. doi: 10.1002/pmic.201700259. Epub 2018 Feb 23.
8
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.肿瘤浸润淋巴细胞凋亡介导的癌症免疫治疗抵抗。
Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.
9
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.肿瘤复发源于自然杀伤细胞和 TNFα 免疫监视的颠覆。
Cancer Immunol Res. 2017 Nov;5(11):1029-1045. doi: 10.1158/2326-6066.CIR-17-0175. Epub 2017 Oct 15.
10
Targeting neoantigens to augment antitumour immunity.靶向新抗原以增强抗肿瘤免疫力。
Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24.
本文引用的文献
1
Immunity to methylcholanthrene-induced sarcomas.对甲基胆蒽诱导肉瘤的免疫性。
J Natl Cancer Inst. 1957 Jun;18(6):769-78.
2
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.同基因肿瘤排斥的机制。宿主选择的进展性变体对各种免疫效应细胞的敏感性。
J Exp Med. 1982 Feb 1;155(2):557-73. doi: 10.1084/jem.155.2.557.
3
Stimulation of cytolytic T lymphocytes by azaguanine-resistant mouse tumor cells in selective HAT medium.在选择性HAT培养基中，用氮杂鸟嘌呤抗性小鼠肿瘤细胞刺激细胞溶解T淋巴细胞。
J Immunol Methods. 1981;46(3):321-6. doi: 10.1016/0022-1759(81)90317-3.
4
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。II. T淋巴细胞介导的细胞溶解作用。
J Exp Med. 1980 Nov 1;152(5):1184-93. doi: 10.1084/jem.152.5.1184.
5
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。I. 同基因小鼠的排斥反应。
J Exp Med. 1980 Nov 1;152(5):1175-83. doi: 10.1084/jem.152.5.1175.
6
T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.T细胞介导的免疫抑制是P815肥大细胞瘤及其转移灶过继性免疫治疗的障碍。
J Exp Med. 1981 Oct 1;154(4):1033-42. doi: 10.1084/jem.154.4.1033.
7
Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells.低剂量照射或针对母细胞性抑制性T细胞免疫后肿瘤生长减缓。
Proc Natl Acad Sci U S A. 1981 Mar;78(3):1809-12. doi: 10.1073/pnas.78.3.1809.
8
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。VI. 由于抗原缺失继发变体导致偶尔逃避宿主排斥反应。
Int J Cancer. 1983 Jan 15;31(1):119-23. doi: 10.1002/ijc.2910310119.
9
Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.通过对小鼠肥大细胞瘤P815进行诱变获得的免疫原性变体。III. 同基因细胞溶解型T淋巴细胞反应的克隆分析。
Eur J Immunol. 1982 May;12(5):401-6. doi: 10.1002/eji.1830120508.
10
Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes.转移性克隆肿瘤细胞变体从肿瘤特异性细胞溶解性T淋巴细胞中逃逸。
J Exp Med. 1981 Aug 1;154(2):557-62. doi: 10.1084/jem.154.2.557.
Zotero 插件